Literature DB >> 30205700

Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets.

Yoshihiro Ito1, Jonathan R Hart1, Peter K Vogt1.   

Abstract

INTRODUCTION: The main regulatory subunits of Class IA phosphatidylinositol 3-kinase (PI3K), p85α and p85β, initiate diverse cellular activities independent of binding to the catalytic subunit p110. Several of these signaling processes directly or indirectly contribute to a regulation of PI3K and could become targets for therapeutic efforts. Areas covered: This review will highlight two general areas of p85 activity: (1) direct interaction with regulatory proteins and with determinants of the cytoskeleton, and (2) a genetic analysis by deletion and domain switches identifying new functions for p85 domains. Expert Opinion: Isoform-specific activities of regulatory subunits have long been at the periphery of the PI3K field. Our understanding of these unique functions of the regulatory subunits is fragmentary and raises many important questions. At this time, there is insufficient information to translate this knowledge into the clinic, but some tempting targets have emerged that could move the field forward with the help of novel technologies in drug design and identification.

Entities:  

Keywords:  Catalytic subunit; direct protein–protein interaction; domain switch; fragment-based inhibitor screening; protein truncation; protein–protein interactions as therapeutic targets; regulatory subunit

Mesh:

Substances:

Year:  2018        PMID: 30205700      PMCID: PMC6197473          DOI: 10.1080/14728222.2018.1522302

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  79 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

Review 2.  Structure and function of phosphoinositide 3-kinases.

Authors:  M P Wymann; L Pirola
Journal:  Biochim Biophys Acta       Date:  1998-12-08

Review 3.  Biological function and histone recognition of family IV bromodomain-containing proteins.

Authors:  Jonathan T Lloyd; Karen C Glass
Journal:  J Cell Physiol       Date:  2017-06-13       Impact factor: 6.384

Review 4.  BRD7: a novel tumor suppressor gene in different cancers.

Authors:  Xin Yu; Zheng Li; Jianxiong Shen
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 5.  Targeting the PI3K pathway in cancer: are we making headway?

Authors:  Filip Janku; Timothy A Yap; Funda Meric-Bernstam
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

6.  Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation.

Authors:  M Dean Chamberlain; Tim Chan; Jennifer C Oberg; Andrea D Hawrysh; Kristy M James; Anurag Saxena; Jim Xiang; Deborah H Anderson
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

7.  Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation.

Authors:  Benjamin G Hale; Ian H Batty; C Peter Downes; Richard E Randall
Journal:  J Biol Chem       Date:  2007-11-20       Impact factor: 5.157

8.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

Review 9.  Structural basis for activation and inhibition of class I phosphoinositide 3-kinases.

Authors:  Oscar Vadas; John E Burke; Xuxiao Zhang; Alex Berndt; Roger L Williams
Journal:  Sci Signal       Date:  2011-10-18       Impact factor: 8.192

10.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

View more
  5 in total

Review 1.  PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Cancer Res       Date:  2020-10-12       Impact factor: 13.312

Review 2.  Impact of p85α Alterations in Cancer.

Authors:  Jeremy D S Marshall; Dielle E Whitecross; Paul Mellor; Deborah H Anderson
Journal:  Biomolecules       Date:  2019-01-15

3.  Comparison of Three Species of Rhubarb in Inhibiting Vascular Endothelial Injury via Regulation of PI3K/AKT/NF-κB Signaling Pathway.

Authors:  Xin Li; Songli Huang; Bingyu Zhuo; Jingyan Hu; Yue Shi; Jiangyi Zhao; Jincheng Tang; Xiuhua Hu; Shengli Wei
Journal:  Oxid Med Cell Longev       Date:  2022-03-28       Impact factor: 7.310

4.  ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.

Authors:  Hasibur Rehman; Darshan S Chandrashekar; Chakravarthi Balabhadrapatruni; Saroj Nepal; Sai Akshaya Hodigere Balasubramanya; Abigail K Shelton; Kasey R Skinner; Ai-Hong Ma; Ting Rao; Sumit Agarwal; Marie-Lisa Eich; Alyncia D Robinson; Gurudatta Naik; Upender Manne; George J Netto; C Ryan Miller; Chong-Xian Pan; Guru Sonpavde; Sooryanarayana Varambally; James E Ferguson
Journal:  JCI Insight       Date:  2022-08-22

5.  Involvement of PI3K/Akt signaling pathway in promoting osteogenesis on titanium implant surfaces modified with novel non-thermal atmospheric plasma.

Authors:  Zheng Zheng; Yanjin He; Li Long; Shuaiqi Gan; Shujiang Chen; Min Zhang; Jia Xu; Ruijie Fu; Yihan Liao; Zhimin Zhu; Hang Wang; Wenchuan Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-09-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.